The low levels of plasma ceruloplasmin (Table S2) observed in the WD patient containing these mutations could be explained by this cellular phenotype, however direct measurements of copper-transport activities of heterodimer (using tyrosinase assay or copper retention) will be necessary to fully understand consequences of compound heterozygosity on ATP7B properties. This evidence concerns the gene ATP7B and Wilson disease.